[1]陈 玲,赵 华,赵培西,等.多柔比星脂质体联合沙利度胺治疗多发性骨髓瘤疗效观察[J].陕西医学杂志,2020,49(3):353-356.
　CHEN Ling,ZHAO Hua,ZHAO Peixi,et al.Clinical efficacy of doxorubicin liposome combined with thalidomide in the treatment of multiple myeloma[J].,2020,49(3):353-356.
点击复制

多柔比星脂质体联合沙利度胺治疗多发性骨髓瘤疗效观察
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年3期
页码:
353-356
栏目:
药物与临床
出版日期:
2020-03-05

文章信息/Info

Title:
Clinical efficacy of doxorubicin liposome combined with thalidomide in the treatment of multiple myeloma
文章编号:
DOI:〖HT5K〗10.3969/j.issn.10007377.2020.03.023
作者:
陈 玲1; 赵 华1; 赵培西1; 朱 涛2; 王 琳3△
1.陕西省肿瘤医院药学部(西安 710061); 2.陕西省友谊医院药剂科(西安710061); 3.陕西省肿瘤医院临床药学室(西安710061)
Author(s):
CHEN Ling; ZHAO Hua; ZHAO Peixi; et al.
Department of Pharmacy,Shaanxi Cancer Hospital(Xi'an 710061)
关键词:
多柔比星脂质体;  沙利度胺;  多发性骨髓瘤;  血红蛋白
Keywords:
Doxorubicin liposome;  Thalidomide;  Multiple myeloma;  Hemoglobin
分类号:
R733.3
文献标志码:
A
摘要:
目的:探究多柔比星脂质体联合沙利度胺治疗多发性骨髓瘤的疗效。方法:选取多发性骨髓瘤患者108例,将其随机分为试验组和对照组各54例。对照组给予VAD方案治疗,试验组给予多柔比星脂质体注射液和沙利度胺治疗,两组均治疗4个疗程。观察记录试验组及对照组血红蛋白浓度、血M蛋白量、骨髓浆细胞变化及不良反应发生情况。结果:经4个疗程治疗后,试验组各项理化指标均较对照组有明显改善,差异有统计学意义; 试验组的治疗有效率及疾病控制率分别为74.1%和85.2%,对照组的治疗有效率及疾病控制率分别为38.9%和51.9%。试验组的治疗有效率及疾病控制率均显著高于对照组,差异有统计学意义; 试验组和对照组在白细胞减少和胃肠道反应发生率的差异无统计学意义; 试验组的血小板减少、脱发、皮疹的发生率明显低于对照组,差异有统计学意义。结论:多柔比星脂质体联合沙利度胺治疗多发性骨髓瘤疗效优于VAD化疗方案,且能降低化疗不良反应发生率,安全性好。
Abstract:
Objective:To investigate the clinical efficacy of doxorubicin liposome combined with thalidomide in the treatment of multiple myeloma.Methods:108 patients with multiple myeloma were randomly divided into experimental group and control group,with 54 cases in each group.The control group was treated with chemotherapeutic regimen VAD.The experimental group was treated with doxorubicin liposome in combination with thalidomide.Both groups were treated for 4 courses.The hemoglobin concentration,blood M protein amount,bone marrow plasma cell changes,and adverse reactions in two groups were observed and recorded.Results:After 4 courses of treatment,the physical and chemical indexes of the experimental group were significantly improved compared with the control group,and the differences were statistically significant.The effective rate and disease control rate of experimental group were 74.1% and 85.2%,respectively.The treatment effective rate and disease control rate of the control group were 38.9% and 51.9%,respectively.The effective rate and disease control rate of experimental group were obviously higher than those of control group,and the differences were statistically significant.There was no significant difference in the incidence of leukopenia and gastrointestinal reactions in two groups.The incidence rates of thrombocytopenia,hair loss,and rash were significantly lower in the experimental group than those in the control group,and the differences were statistically significant.Conclusion:Compared with chemotherapeutic regimen VAD,the treatment of doxorubicin liposome in combination with thalidomide for multiple myeloma show a better clinical effect,and has good security.

参考文献/References:

[1] Scott K,Hayden PJ,Howman A,et al.Bortezomib for the treatment of multiple myeloma[J].Expert Rev Hematol,2014,7(7):173-185.
[2] 邢 玉.益肾强骨扶正法联合化疗治疗多发性骨髓瘤临床研究[J].陕西中医,2018,39(7):121-123,132.
[3] Husseiny NME,Kasem N,Azeeim HAE,et al.Multiple myeloma:a descriptive study of 217 Egyptian patients[J].Ann Hematol,2014,93(1):141-145.
[4] De SV,Za T,Rossi E.Venous thromboembolism in multiple myeloma[J].Semin Thromb Hemost,2014,40(3):338-347.
[5] 高秋英,王 晖,王 一,等.乌苯美司联合VAD方案治疗多发性骨髓瘤疗效观察[J].陕西医学杂志,2015,46(12):117-118,131.
[6] Runcie KD,Mark TM.Novel induction regimens in multiple myeloma[J].Curr Hematol Malig R,2015,10(4):1-7.
[7] 师 勇,田 龙,王 萍.多发性骨髓瘤32例磁共振显像分型与临床分期对比分析[J].陕西医学杂志,2016,11(45):1499-1501.
[8] Colombo R,Gallipoli P,Castelli R.Thrombosis and hemostatic abnormalities in hematological malignancies[J].Cl lymph Myelom Leuk,2014,14(6):441-450.
[9] Jurczyszyn A,Legiec W,Helbig G,et al.New drugs in multiple myeloma - role of carfilzomib and pomalidomide[J].Wspolczesna Onkol,2014,18(1):17-21.
[10] Baz RC,Shain KH,Hussein MA,et al.Phase II study of pegylated liposomal doxorubicin,low-dose dexamethasone,and lenalidomide in patients with newly diagnosed multiple myeloma[J].American Journal of Hematology,2014,89(1):62-67.
[11] Kouroukis TC,Baldassarre FG,Haynes AE,et al.Bortezomib in multiple myeloma:systematic review and clinical considerations[J].Curr Oncol,2014,21(4):573-603.
[12] 张鹏宇,陈银霞,曹星梅,等.硼替佐米为主的化疗方案治疗初治多发性骨髓瘤疗效观察以及对IL-6和铁蛋白的影响[J].陕西医学杂志,2016,45(11):1511-1514.
[13] Wang L,Xu YL,Zhang XQ.Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma:a meta-analysis of 14 randomized controlled trials[J].Leukemia Lymphoma,2014,55(7):1479-88.
[14] 高晓艳,田小清,吕润林,等.小剂量沙利度胺联合小剂量VAD方案治疗老年多发性骨髓瘤的疗效观察[J].陕西医学杂志,2014,65(12):20-21.
[15] Richardson PG,Mitsiades C,Schlossman R,et al.Bortezomib in the front-line treatment of multiple myeloma[J].Expertrev Anticanc,2014,8(7):1053-1072.
[16] 陈 瑾,王晓宁.反应停联合化疗治疗43例多发性骨髓瘤临床观察[J].陕西医学杂志,2015,46(8):66-68.
[17] Cook G,Williams C,Brown JM,et al.High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation(NCRI Myeloma X Relapse [Intensive trial]):a randomised,open-label[J].Lancet Oncol,2014,15(8):874-885.
[18] Mikhael JR.A practical approach to relapsed multiple myeloma[J].Hematology,2014,2014(1):262-267.
[19] Griffin PT,Viet Q,Ho Pharm DBCOP,et al.A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma[J].Cancer,2015,121(20):3622-3630.

相似文献/References:

[1]杨 婧,何家锐,孙红兵,等.沙利度胺对类风湿关节炎滑膜细胞及外周血单个核细胞分泌肿瘤坏死因子-α和血管内皮生长因子的影响及机制研究[J].陕西医学杂志,2022,51(12):1501.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.008]
　YANG Jing,HE Jiarui,SUN Hongbing,et al.Effects of thalidomide on secretion of TNF-α and VEGF in fibroblast-like synoviocytes and peripheral blood mononuclear cells in patients with rheumatoid arthritis and its mechanism[J].,2022,51(3):1501.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.008]

更新日期/Last Update: 2020-03-25